Novo Nordisk Stock Tumbles as Ozempic Maker Sets Out 2030 Goals

Novo Nordisk shares tumbled on Monday as the Ozempic maker laid out its strategic goals through 2030 during an investor day in London. Copenhagen-listed shares closed 7.7% lower in what TIKR reported as their worst day since February, while other sources noted drops ranging from 6% to as much as 9%.

CEO Mike Doustdar and company management used the event to address the drugmaker's broader future, announcing plans to launch more than five blockbuster drugs by 2030 and serve over 60 million patients globally. The strategic reset follows a turbulent stretch for the company, which saw its stock decline 27% over the previous 12 months and fall 19% year to date heading into Monday.

What are the main 2030 targets set by management?

Management outlined a series of volume, pipeline, and financial goals designed to shift the company's trajectory through the end of the decade. The plan focuses heavily on expanding oral GLP-1 treatments and diversifying beyond diabetes and obesity into cardiovascular disease, liver disease, and blood and endocrine disorders.

According to the corporate announcements in London, key operational targets include:

• Serving over 60 million patients globally by 2030.
• Launching at least five multiblockbuster or blockbuster drugs by the end of the decade.
• Scaling manufacturing to supply 15 million people with oral obesity treatments by 2030.
• Targeting over 150 billion Danish kroner, roughly $23 billion USD, in risk-adjusted pipeline sales by 2035.
• Delivering compound annual revenue growth between 2026 and 2030 in line with big pharma peers like Eli Lilly, AstraZeneca, Amgen, Biogen, Merck, AbbVie, and Novartis.

Out-of-pocket and self-pay channels currently account for 50% of the Wegovy franchise, with direct cash purchases making up 90% of demand for the Wegovy pill, according to Finimize.

Why did investors react negatively to the strategy?

Investors pushed back on the timeline and the lack of immediate solutions for near-term pressures, sending the share price down to $37.32 as reported by Grafa, well off its 52-week high of $64. Savings Economist Per Hansen of Nordnet told TIKR that investors had hoped for a project miracle to turn short-term momentum around, noting that such a miracle does not exist. Investment Strategist Jacob Pedersen of Middelfart Sparekasse added that investors are very particular about what they want from the company and the new targets did not meet those expectations.

Management also addressed the looming expiration of the semaglutide patent in the U.S., which begins in 2032. CEO Mike Doustdar called it the elephant in the room, acknowledging that the company built the market and now faces nearly every major pharmaceutical competitor. Investor pushback highlighted that management's plan left questions unanswered regarding how the company will defend its pricing power post-patent expiration.

What happens next for the pipeline?

Looking ahead, management pointed to a multi-year rollout of follow-on products. This pipeline progression includes advancing treatments such as CagriSema as soon as next year. Alongside the strategic rollout, the company announced a corporate rebrand to use the shorter 'Novo' name in day-to-day communications while maintaining Novo Nordisk A/S as its legal name.